Stockscreener 앱 받기
0.92
3.29%
0.0293
시간 외 거래:
.90
-0.02
-2.17%
전일 마감가:
$0.8907
열려 있는:
$0.91
하루 거래량:
330.61K
Relative Volume:
0.95
시가총액:
$41.49M
수익:
$1.12M
순이익/손실:
$-11.17M
주가수익비율:
-2.9105
EPS:
-0.3161
순현금흐름:
$-10.98M
1주 성능:
+6.41%
1개월 성능:
+17.47%
6개월 성능:
+2.22%
1년 성능:
-33.33%
1일 변동 폭
$0.889
$0.94
1주일 범위
$0.8407
$0.94
52주 변동 폭
$0.7006
$1.45
Renovorx Inc Stock (RNXT) Company Profile
명칭
Renovorx Inc
전화
408-800-2649
주소
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
0.92 | 41.49M | 1.12M | -11.17M | -10.98M | -0.3161 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Renovorx Inc 주식(RNXT)의 최신 뉴스
RenovoRx Inc (RNXT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
RenovoRx Inc (RNXT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
RenovoRx Inc (RNXT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
RenovoRx Inc (RNXT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
RenovoRx Inc (RNXT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RenovoRx Inc (RNXT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
RenovoRx Inc (RNXT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
RNXT Q1 2026 Earnings: EPS Misses Estimates as Pre‑Revenue Biotech Advances Clinical ProgramsAnalyst Consensus Shift - newsline.com
RNXT News | RENOVORX INC (NASDAQ:RNXT) - ChartMill
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP in Locally Advanced Pancreatic Cancer - Investing News Network
RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer - The Manila Times
Targeted artery chemo saw 52% tumor activity drop in pancreatic cancer case - Stock Titan
RenovoRx (RNXT) Q1 2026 Earnings: EPS Falls Short of Estimates as Pre-Revenue Biotech Advances Clinical PipelineGuidance Update - newsline.com
RNXT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Oncology Firm Advances Clinical PipelineEarnings Whisper Number - newsline.com
RenovoRx Inc. (RNXT) Holds Steady Near Support as Investors Eye ResistanceInstitutional Flow Picks - newsline.com
RNXT Q1 2026 Earnings: EPS Miss Widens Losses as Stock Declines 10.6%Post-Earnings Drift - newsline.com
RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd - Investing News Network
RNXT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances Clinical PipelinePre-Announcement Alert - newsline.com
Stock Ratings | Raymond James raised its target price for Micron (MU) to $1,100; Ascendiant raised its target price for RenovoRx (RNXT) to $14, indicating a potential upside of 1,420.58% - Sahm
RNXT Maintains Buy Rating by Ascendiant Capital -- Price Target Raised to $14.00 - GuruFocus
RenovoRx (RNXT) Dips Over 8% as Stock Tests Key Support LevelsCall Resistance - newsline.com
New chemotherapy delivery method scores FDA orphan drug status - Rare Cancer News
RNXT Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Advances TrialsEarnings Preview - The Legal Advocate
RenovoRx Inc. (RNXT) Moves Higher by 6.2% as Shares Approach Resistance at $1.04Volatility Term Structure - The Legal Advocate
RenovoRx (RNXT) Advances 6.2% as Momentum Builds Toward ResistanceCall Spread Alert - The Legal Advocate
RenovoRx receives FDA orphan drug designation for oxaliplatin - Investing.com UK
RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer - Investing News Network
RenovoRx receives FDA orphan drug designation for oxaliplatin By Investing.com - Investing.com Australia
RenovoRx gets FDA orphan drug designation for oxaliplatin to treat pancreatic cancer - marketscreener.com
RenovoRx Gets FDA Orphan Drug Designation For Oxaliplatin To Treat Pancreatic Cancer - TradingView
FDA grants orphan status to oxaliplatin for hard-to-treat pancreatic cancer - Stock Titan
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP Platform Presented at the 2026 ASCO Annual Meeting - Investing News Network
RenovoRx reports pharmacokinetic data from pancreatic trial By Investing.com - Investing.com Nigeria
RenovoRx reports pharmacokinetic data from pancreatic trial - Investing.com
RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting - The Manila Times
Pancreatic cancer study tests drug delivery that may cut side effects - Stock Titan
RenovoRx Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Advances PipelineEPS Estimate Trend - Newser
RenovoRx Inc. (RNXT) Q1 2026 Earnings: Clinical-Stage Biotech Reports Wider-Than-Expected Loss; Stock Holds SteadyCrowd Stock Picks - Newser
RenovoRx Q1 2026 Earnings: EPS Miss as Pre-Revenue Biotech Continues Clinical DevelopmentNet Income Trends - Newser
RenovoRx Inc. (RNXT) Hovers Near Support as Thin Trading PersistsExpert Momentum Signals - Newser
RenovoRx (RNXT) Slides to $0.88, Nearing Critical SupportRetail Driven Moves - Newser
RenovoRx CFO Mark Voll buys $19,690 in common stock By Investing.com - Investing.com Canada
RenovoRx CFO Mark Voll buys $19,690 in common stock - Investing.com India
RenovoRx (RNXT) Q1 2026 Results Trail Estimates: A Deeper LookGuidance Accuracy Score - Newser
Renovorx Inc (RNXT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.74%
1.44%
자본화:
|
볼륨(24시간):